Clinical Trial Update: Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial [Phase 2]

View source ↗

Summary

Phase 2 pilot trial assessing glutamatergic modulation to treat depressive symptoms in patients with Post-acute Sequelae of COVID-19; the study is active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Post-acute Sequelae of COVID-19

Drugs mentioned

• Investigational glutamatergic modulator

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Post-acute Sequelae of COVID-19, Depressive Symptoms | Phase 2 | Status: ACTIVE_NOT_RECRUITING